Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd. (300357.SZ) announced that after careful evaluation by the management team, the company has decided to terminate the R&D project for Aspergillus Fumigatus Skin Prick Test Solution. The decision was made based on comprehensive considerations including project progress and development risks, aiming to optimize R&D resource allocation and focus on more promising projects in the pipeline. The company will not proceed with further clinical trials for this project.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments